Oxford Cancer is developing and commercialising a suite of colorectal cancer biomarker tests to improve the current treatment pathway.
Oxford Cancer Biomarkers's investors include Longwall Venture, NHS England, Panacea Capital, Esperante Ventures, Kwang Dong Pharmaceutical.
Oxford Cancer Biomarkers is headquartered in Oxford, United Kingdom.
Oxford Cancer is developing and commercialising a suite of colorectal cancer biomarker tests to improve the current treatment pathway.
Oxford Cancer Biomarkers is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Oxford Cancer Biomarkers — Funding & Investors." VCBacked, April 3, 2023, https://www.vcbacked.co/company/oxford-cancer-biomarkers. Accessed August 14, 2026.
VCBacked. (2023). Oxford Cancer Biomarkers — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/oxford-cancer-biomarkers
{{cite web |title=Oxford Cancer Biomarkers — Funding & Investors |url=https://www.vcbacked.co/company/oxford-cancer-biomarkers |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated